Drug-Resistant Tuberculosis Treatment Market, Global Outlook and Forecast 2022-2028

June 2022 | 102 pages | ID: DA66C1FD9617EN
Market Monitor Global

Abstracts

This report contains market size and forecasts of Drug-Resistant Tuberculosis Treatment in Global, including the following market information:

Global Drug-Resistant Tuberculosis Treatment Market Revenue, 2017-2022, 2023-2028, ($ millions)

Global top five companies in 2021 (%)

The global Drug-Resistant Tuberculosis Treatment market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period 2022-2028.

The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.

First-Line Anti-TB Drugs Segment to Reach $ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of Drug-Resistant Tuberculosis Treatment include Sanofi, Novartis AG, Endo International plc, CMP Pharma, STI Pharma LLC, Akorn Incorporated, Lupin, Johnson & Johnson Services Inc. and Macleods Pharmaceuticals Ltd, etc. In 2021, the global top five players have a share approximately % in terms of revenue.

MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Drug-Resistant Tuberculosis Treatment companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Drug-Resistant Tuberculosis Treatment Market, by Type, 2017-2022, 2023-2028 ($ millions)

Global Drug-Resistant Tuberculosis Treatment Market Segment Percentages, by Type, 2021 (%)

• First-Line Anti-TB Drugs
• Second-Line Anti-TB Drugs
• Others

Global Drug-Resistant Tuberculosis Treatment Market, by Application, 2017-2022, 2023-2028 ($ millions)

Global Drug-Resistant Tuberculosis Treatment Market Segment Percentages, by Application, 2021 (%)

• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy
• Others

Global Drug-Resistant Tuberculosis Treatment Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)

Global Drug-Resistant Tuberculosis Treatment Market Segment Percentages, By Region and Country, 2021 (%)

• North America
• US
• Canada
• Mexico
• Europe
• Germany
• France
• U.K.
• Italy
• Russia
• Nordic Countries
• Benelux
• Rest of Europe
• Asia
• China
• Japan
• South Korea
• Southeast Asia
• India
• Rest of Asia
• South America
• Brazil
• Argentina
• Rest of South America
• Middle East & Africa
• Turkey
• Israel
• Saudi Arabia
• UAE
• Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

Key companies Drug-Resistant Tuberculosis Treatment revenues in global market, 2017-2022 (estimated), ($ millions)

Key companies Drug-Resistant Tuberculosis Treatment revenues share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

• Sanofi
• Novartis AG
• Endo International plc
• CMP Pharma
• STI Pharma LLC
• Akorn Incorporated
• Lupin
• Johnson & Johnson Services Inc.
• Macleods Pharmaceuticals Ltd
• Pfizer Inc
• Hikma Pharmaceuticals PLC
• Lannett
• Mylan N.V.
• Teva Pharmaceutical Industries Ltd
• Fresenius Kabi AG

Contents

1 INTRODUCTION TO RESEARCH & ANALYSIS REPORTS

1.1 Drug-Resistant Tuberculosis Treatment Market Definition
1.2 Market Segments
  1.2.1 Market by Type
  1.2.2 Market by Application
1.3 Global Drug-Resistant Tuberculosis Treatment Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
  1.5.1 Research Methodology
  1.5.2 Research Process
  1.5.3 Base Year
  1.5.4 Report Assumptions & Caveats

2 GLOBAL DRUG-RESISTANT TUBERCULOSIS TREATMENT OVERALL MARKET SIZE

2.1 Global Drug-Resistant Tuberculosis Treatment Market Size: 2021 VS 2028
2.2 Global Drug-Resistant Tuberculosis Treatment Market Size, Prospects & Forecasts: 2017-2028
2.3 Key Market Trends, Opportunity, Drivers and Restraints
  2.3.1 Market Opportunities & Trends
  2.3.2 Market Drivers
  2.3.3 Market Restraints

3 COMPANY LANDSCAPE

3.1 Top Drug-Resistant Tuberculosis Treatment Players in Global Market
3.2 Top Global Drug-Resistant Tuberculosis Treatment Companies Ranked by Revenue
3.3 Global Drug-Resistant Tuberculosis Treatment Revenue by Companies
3.4 Top 3 and Top 5 Drug-Resistant Tuberculosis Treatment Companies in Global Market, by Revenue in 2021
3.5 Global Companies Drug-Resistant Tuberculosis Treatment Product Type
3.6 Tier 1, Tier 2 and Tier 3 Drug-Resistant Tuberculosis Treatment Players in Global Market
  3.6.1 List of Global Tier 1 Drug-Resistant Tuberculosis Treatment Companies
  3.6.2 List of Global Tier 2 and Tier 3 Drug-Resistant Tuberculosis Treatment Companies

4 MARKET SIGHTS BY PRODUCT

4.1 Overview
  4.1.1 by Type - Global Drug-Resistant Tuberculosis Treatment Market Size Markets, 2021 & 2028
  4.1.2 First-Line Anti-TB Drugs
  4.1.3 Second-Line Anti-TB Drugs
  4.1.4 Others
4.2 By Type - Global Drug-Resistant Tuberculosis Treatment Revenue & Forecasts
  4.2.1 By Type - Global Drug-Resistant Tuberculosis Treatment Revenue, 2017-2022
  4.2.2 By Type - Global Drug-Resistant Tuberculosis Treatment Revenue, 2023-2028
  4.2.3 By Type - Global Drug-Resistant Tuberculosis Treatment Revenue Market Share, 2017-2028

5 SIGHTS BY APPLICATION

5.1 Overview
  5.1.1 By Application - Global Drug-Resistant Tuberculosis Treatment Market Size, 2021 & 2028
  5.1.2 Hospital Pharmacy
  5.1.3 Online Pharmacy
  5.1.4 Retail Pharmacy
  5.1.5 Others
5.2 By Application - Global Drug-Resistant Tuberculosis Treatment Revenue & Forecasts
  5.2.1 By Application - Global Drug-Resistant Tuberculosis Treatment Revenue, 2017-2022
  5.2.2 By Application - Global Drug-Resistant Tuberculosis Treatment Revenue, 2023-2028
  5.2.3 By Application - Global Drug-Resistant Tuberculosis Treatment Revenue Market Share, 2017-2028

6 SIGHTS BY REGION

6.1 By Region - Global Drug-Resistant Tuberculosis Treatment Market Size, 2021 & 2028
6.2 By Region - Global Drug-Resistant Tuberculosis Treatment Revenue & Forecasts
  6.2.1 By Region - Global Drug-Resistant Tuberculosis Treatment Revenue, 2017-2022
  6.2.2 By Region - Global Drug-Resistant Tuberculosis Treatment Revenue, 2023-2028
  6.2.3 By Region - Global Drug-Resistant Tuberculosis Treatment Revenue Market Share, 2017-2028
6.3 North America
  6.3.1 By Country - North America Drug-Resistant Tuberculosis Treatment Revenue, 2017-2028
  6.3.2 US Drug-Resistant Tuberculosis Treatment Market Size, 2017-2028
  6.3.3 Canada Drug-Resistant Tuberculosis Treatment Market Size, 2017-2028
  6.3.4 Mexico Drug-Resistant Tuberculosis Treatment Market Size, 2017-2028
6.4 Europe
  6.4.1 By Country - Europe Drug-Resistant Tuberculosis Treatment Revenue, 2017-2028
  6.4.2 Germany Drug-Resistant Tuberculosis Treatment Market Size, 2017-2028
  6.4.3 France Drug-Resistant Tuberculosis Treatment Market Size, 2017-2028
  6.4.4 U.K. Drug-Resistant Tuberculosis Treatment Market Size, 2017-2028
  6.4.5 Italy Drug-Resistant Tuberculosis Treatment Market Size, 2017-2028
  6.4.6 Russia Drug-Resistant Tuberculosis Treatment Market Size, 2017-2028
  6.4.7 Nordic Countries Drug-Resistant Tuberculosis Treatment Market Size, 2017-2028
  6.4.8 Benelux Drug-Resistant Tuberculosis Treatment Market Size, 2017-2028
6.5 Asia
  6.5.1 By Region - Asia Drug-Resistant Tuberculosis Treatment Revenue, 2017-2028
  6.5.2 China Drug-Resistant Tuberculosis Treatment Market Size, 2017-2028
  6.5.3 Japan Drug-Resistant Tuberculosis Treatment Market Size, 2017-2028
  6.5.4 South Korea Drug-Resistant Tuberculosis Treatment Market Size, 2017-2028
  6.5.5 Southeast Asia Drug-Resistant Tuberculosis Treatment Market Size, 2017-2028
  6.5.6 India Drug-Resistant Tuberculosis Treatment Market Size, 2017-2028
6.6 South America
  6.6.1 By Country - South America Drug-Resistant Tuberculosis Treatment Revenue, 2017-2028
  6.6.2 Brazil Drug-Resistant Tuberculosis Treatment Market Size, 2017-2028
  6.6.3 Argentina Drug-Resistant Tuberculosis Treatment Market Size, 2017-2028
6.7 Middle East & Africa
  6.7.1 By Country - Middle East & Africa Drug-Resistant Tuberculosis Treatment Revenue, 2017-2028
  6.7.2 Turkey Drug-Resistant Tuberculosis Treatment Market Size, 2017-2028
  6.7.3 Israel Drug-Resistant Tuberculosis Treatment Market Size, 2017-2028
  6.7.4 Saudi Arabia Drug-Resistant Tuberculosis Treatment Market Size, 2017-2028
  6.7.5 UAE Drug-Resistant Tuberculosis Treatment Market Size, 2017-2028

7 PLAYERS PROFILES

7.1 Sanofi
  7.1.1 Sanofi Corporate Summary
  7.1.2 Sanofi Business Overview
  7.1.3 Sanofi Drug-Resistant Tuberculosis Treatment Major Product Offerings
  7.1.4 Sanofi Drug-Resistant Tuberculosis Treatment Revenue in Global Market (2017-2022)
  7.1.5 Sanofi Key News
7.2 Novartis AG
  7.2.1 Novartis AG Corporate Summary
  7.2.2 Novartis AG Business Overview
  7.2.3 Novartis AG Drug-Resistant Tuberculosis Treatment Major Product Offerings
  7.2.4 Novartis AG Drug-Resistant Tuberculosis Treatment Revenue in Global Market (2017-2022)
  7.2.5 Novartis AG Key News
7.3 Endo International plc
  7.3.1 Endo International plc Corporate Summary
  7.3.2 Endo International plc Business Overview
  7.3.3 Endo International plc Drug-Resistant Tuberculosis Treatment Major Product Offerings
  7.3.4 Endo International plc Drug-Resistant Tuberculosis Treatment Revenue in Global Market (2017-2022)
  7.3.5 Endo International plc Key News
7.4 CMP Pharma
  7.4.1 CMP Pharma Corporate Summary
  7.4.2 CMP Pharma Business Overview
  7.4.3 CMP Pharma Drug-Resistant Tuberculosis Treatment Major Product Offerings
  7.4.4 CMP Pharma Drug-Resistant Tuberculosis Treatment Revenue in Global Market (2017-2022)
  7.4.5 CMP Pharma Key News
7.5 STI Pharma LLC
  7.5.1 STI Pharma LLC Corporate Summary
  7.5.2 STI Pharma LLC Business Overview
  7.5.3 STI Pharma LLC Drug-Resistant Tuberculosis Treatment Major Product Offerings
  7.5.4 STI Pharma LLC Drug-Resistant Tuberculosis Treatment Revenue in Global Market (2017-2022)
  7.5.5 STI Pharma LLC Key News
7.6 Akorn Incorporated
  7.6.1 Akorn Incorporated Corporate Summary
  7.6.2 Akorn Incorporated Business Overview
  7.6.3 Akorn Incorporated Drug-Resistant Tuberculosis Treatment Major Product Offerings
  7.6.4 Akorn Incorporated Drug-Resistant Tuberculosis Treatment Revenue in Global Market (2017-2022)
  7.6.5 Akorn Incorporated Key News
7.7 Lupin
  7.7.1 Lupin Corporate Summary
  7.7.2 Lupin Business Overview
  7.7.3 Lupin Drug-Resistant Tuberculosis Treatment Major Product Offerings
  7.7.4 Lupin Drug-Resistant Tuberculosis Treatment Revenue in Global Market (2017-2022)
  7.7.5 Lupin Key News
7.8 Johnson & Johnson Services Inc.
  7.8.1 Johnson & Johnson Services Inc. Corporate Summary
  7.8.2 Johnson & Johnson Services Inc. Business Overview
  7.8.3 Johnson & Johnson Services Inc. Drug-Resistant Tuberculosis Treatment Major Product Offerings
  7.8.4 Johnson & Johnson Services Inc. Drug-Resistant Tuberculosis Treatment Revenue in Global Market (2017-2022)
  7.8.5 Johnson & Johnson Services Inc. Key News
7.9 Macleods Pharmaceuticals Ltd
  7.9.1 Macleods Pharmaceuticals Ltd Corporate Summary
  7.9.2 Macleods Pharmaceuticals Ltd Business Overview
  7.9.3 Macleods Pharmaceuticals Ltd Drug-Resistant Tuberculosis Treatment Major Product Offerings
  7.9.4 Macleods Pharmaceuticals Ltd Drug-Resistant Tuberculosis Treatment Revenue in Global Market (2017-2022)
  7.9.5 Macleods Pharmaceuticals Ltd Key News
7.10 Pfizer Inc
  7.10.1 Pfizer Inc Corporate Summary
  7.10.2 Pfizer Inc Business Overview
  7.10.3 Pfizer Inc Drug-Resistant Tuberculosis Treatment Major Product Offerings
  7.10.4 Pfizer Inc Drug-Resistant Tuberculosis Treatment Revenue in Global Market (2017-2022)
  7.10.5 Pfizer Inc Key News
7.11 Hikma Pharmaceuticals PLC
  7.11.1 Hikma Pharmaceuticals PLC Corporate Summary
  7.11.2 Hikma Pharmaceuticals PLC Business Overview
  7.11.3 Hikma Pharmaceuticals PLC Drug-Resistant Tuberculosis Treatment Major Product Offerings
  7.11.4 Hikma Pharmaceuticals PLC Drug-Resistant Tuberculosis Treatment Revenue in Global Market (2017-2022)
  7.11.5 Hikma Pharmaceuticals PLC Key News
7.12 Lannett
  7.12.1 Lannett Corporate Summary
  7.12.2 Lannett Business Overview
  7.12.3 Lannett Drug-Resistant Tuberculosis Treatment Major Product Offerings
  7.12.4 Lannett Drug-Resistant Tuberculosis Treatment Revenue in Global Market (2017-2022)
  7.12.5 Lannett Key News
7.13 Mylan N.V.
  7.13.1 Mylan N.V. Corporate Summary
  7.13.2 Mylan N.V. Business Overview
  7.13.3 Mylan N.V. Drug-Resistant Tuberculosis Treatment Major Product Offerings
  7.13.4 Mylan N.V. Drug-Resistant Tuberculosis Treatment Revenue in Global Market (2017-2022)
  7.13.5 Mylan N.V. Key News
7.14 Teva Pharmaceutical Industries Ltd
  7.14.1 Teva Pharmaceutical Industries Ltd Corporate Summary
  7.14.2 Teva Pharmaceutical Industries Ltd Business Overview
  7.14.3 Teva Pharmaceutical Industries Ltd Drug-Resistant Tuberculosis Treatment Major Product Offerings
  7.14.4 Teva Pharmaceutical Industries Ltd Drug-Resistant Tuberculosis Treatment Revenue in Global Market (2017-2022)
  7.14.5 Teva Pharmaceutical Industries Ltd Key News
7.15 Fresenius Kabi AG
  7.15.1 Fresenius Kabi AG Corporate Summary
  7.15.2 Fresenius Kabi AG Business Overview
  7.15.3 Fresenius Kabi AG Drug-Resistant Tuberculosis Treatment Major Product Offerings
  7.15.4 Fresenius Kabi AG Drug-Resistant Tuberculosis Treatment Revenue in Global Market (2017-2022)
  7.15.5 Fresenius Kabi AG Key News

8 CONCLUSION

9 APPENDIX

9.1 Note
9.2 Examples of Clients
9.3 Disclaimer

List Of Tables

LIST OF TABLES

Table 1. Drug-Resistant Tuberculosis Treatment Market Opportunities & Trends in Global Market
Table 2. Drug-Resistant Tuberculosis Treatment Market Drivers in Global Market
Table 3. Drug-Resistant Tuberculosis Treatment Market Restraints in Global Market
Table 4. Key Players of Drug-Resistant Tuberculosis Treatment in Global Market
Table 5. Top Drug-Resistant Tuberculosis Treatment Players in Global Market, Ranking by Revenue (2021)
Table 6. Global Drug-Resistant Tuberculosis Treatment Revenue by Companies, (US$, Mn), 2017-2022
Table 7. Global Drug-Resistant Tuberculosis Treatment Revenue Share by Companies, 2017-2022
Table 8. Global Companies Drug-Resistant Tuberculosis Treatment Product Type
Table 9. List of Global Tier 1 Drug-Resistant Tuberculosis Treatment Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Drug-Resistant Tuberculosis Treatment Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 11. By Type – Global Drug-Resistant Tuberculosis Treatment Revenue, (US$, Mn), 2021 & 2028
Table 12. By Type - Drug-Resistant Tuberculosis Treatment Revenue in Global (US$, Mn), 2017-2022
Table 13. By Type - Drug-Resistant Tuberculosis Treatment Revenue in Global (US$, Mn), 2023-2028
Table 14. By Application – Global Drug-Resistant Tuberculosis Treatment Revenue, (US$, Mn), 2021 & 2028
Table 15. By Application - Drug-Resistant Tuberculosis Treatment Revenue in Global (US$, Mn), 2017-2022
Table 16. By Application - Drug-Resistant Tuberculosis Treatment Revenue in Global (US$, Mn), 2023-2028
Table 17. By Region – Global Drug-Resistant Tuberculosis Treatment Revenue, (US$, Mn), 2021 & 2028
Table 18. By Region - Global Drug-Resistant Tuberculosis Treatment Revenue (US$, Mn), 2017-2022
Table 19. By Region - Global Drug-Resistant Tuberculosis Treatment Revenue (US$, Mn), 2023-2028
Table 20. By Country - North America Drug-Resistant Tuberculosis Treatment Revenue, (US$, Mn), 2017-2022
Table 21. By Country - North America Drug-Resistant Tuberculosis Treatment Revenue, (US$, Mn), 2023-2028
Table 22. By Country - Europe Drug-Resistant Tuberculosis Treatment Revenue, (US$, Mn), 2017-2022
Table 23. By Country - Europe Drug-Resistant Tuberculosis Treatment Revenue, (US$, Mn), 2023-2028
Table 24. By Region - Asia Drug-Resistant Tuberculosis Treatment Revenue, (US$, Mn), 2017-2022
Table 25. By Region - Asia Drug-Resistant Tuberculosis Treatment Revenue, (US$, Mn), 2023-2028
Table 26. By Country - South America Drug-Resistant Tuberculosis Treatment Revenue, (US$, Mn), 2017-2022
Table 27. By Country - South America Drug-Resistant Tuberculosis Treatment Revenue, (US$, Mn), 2023-2028
Table 28. By Country - Middle East & Africa Drug-Resistant Tuberculosis Treatment Revenue, (US$, Mn), 2017-2022
Table 29. By Country - Middle East & Africa Drug-Resistant Tuberculosis Treatment Revenue, (US$, Mn), 2023-2028
Table 30. Sanofi Corporate Summary
Table 31. Sanofi Drug-Resistant Tuberculosis Treatment Product Offerings
Table 32. Sanofi Drug-Resistant Tuberculosis Treatment Revenue (US$, Mn), (2017-2022)
Table 33. Novartis AG Corporate Summary
Table 34. Novartis AG Drug-Resistant Tuberculosis Treatment Product Offerings
Table 35. Novartis AG Drug-Resistant Tuberculosis Treatment Revenue (US$, Mn), (2017-2022)
Table 36. Endo International plc Corporate Summary
Table 37. Endo International plc Drug-Resistant Tuberculosis Treatment Product Offerings
Table 38. Endo International plc Drug-Resistant Tuberculosis Treatment Revenue (US$, Mn), (2017-2022)
Table 39. CMP Pharma Corporate Summary
Table 40. CMP Pharma Drug-Resistant Tuberculosis Treatment Product Offerings
Table 41. CMP Pharma Drug-Resistant Tuberculosis Treatment Revenue (US$, Mn), (2017-2022)
Table 42. STI Pharma LLC Corporate Summary
Table 43. STI Pharma LLC Drug-Resistant Tuberculosis Treatment Product Offerings
Table 44. STI Pharma LLC Drug-Resistant Tuberculosis Treatment Revenue (US$, Mn), (2017-2022)
Table 45. Akorn Incorporated Corporate Summary
Table 46. Akorn Incorporated Drug-Resistant Tuberculosis Treatment Product Offerings
Table 47. Akorn Incorporated Drug-Resistant Tuberculosis Treatment Revenue (US$, Mn), (2017-2022)
Table 48. Lupin Corporate Summary
Table 49. Lupin Drug-Resistant Tuberculosis Treatment Product Offerings
Table 50. Lupin Drug-Resistant Tuberculosis Treatment Revenue (US$, Mn), (2017-2022)
Table 51. Johnson & Johnson Services Inc. Corporate Summary
Table 52. Johnson & Johnson Services Inc. Drug-Resistant Tuberculosis Treatment Product Offerings
Table 53. Johnson & Johnson Services Inc. Drug-Resistant Tuberculosis Treatment Revenue (US$, Mn), (2017-2022)
Table 54. Macleods Pharmaceuticals Ltd Corporate Summary
Table 55. Macleods Pharmaceuticals Ltd Drug-Resistant Tuberculosis Treatment Product Offerings
Table 56. Macleods Pharmaceuticals Ltd Drug-Resistant Tuberculosis Treatment Revenue (US$, Mn), (2017-2022)
Table 57. Pfizer Inc Corporate Summary
Table 58. Pfizer Inc Drug-Resistant Tuberculosis Treatment Product Offerings
Table 59. Pfizer Inc Drug-Resistant Tuberculosis Treatment Revenue (US$, Mn), (2017-2022)
Table 60. Hikma Pharmaceuticals PLC Corporate Summary
Table 61. Hikma Pharmaceuticals PLC Drug-Resistant Tuberculosis Treatment Product Offerings
Table 62. Hikma Pharmaceuticals PLC Drug-Resistant Tuberculosis Treatment Revenue (US$, Mn), (2017-2022)
Table 63. Lannett Corporate Summary
Table 64. Lannett Drug-Resistant Tuberculosis Treatment Product Offerings
Table 65. Lannett Drug-Resistant Tuberculosis Treatment Revenue (US$, Mn), (2017-2022)
Table 66. Mylan N.V. Corporate Summary
Table 67. Mylan N.V. Drug-Resistant Tuberculosis Treatment Product Offerings
Table 68. Mylan N.V. Drug-Resistant Tuberculosis Treatment Revenue (US$, Mn), (2017-2022)
Table 69. Teva Pharmaceutical Industries Ltd Corporate Summary
Table 70. Teva Pharmaceutical Industries Ltd Drug-Resistant Tuberculosis Treatment Product Offerings
Table 71. Teva Pharmaceutical Industries Ltd Drug-Resistant Tuberculosis Treatment Revenue (US$, Mn), (2017-2022)
Table 72. Fresenius Kabi AG Corporate Summary
Table 73. Fresenius Kabi AG Drug-Resistant Tuberculosis Treatment Product Offerings
Table 74. Fresenius Kabi AG Drug-Resistant Tuberculosis Treatment Revenue (US$, Mn), (2017-2022)

List Of Figures

LIST OF FIGURES

Figure 1. Drug-Resistant Tuberculosis Treatment Segment by Type in 2021
Figure 2. Drug-Resistant Tuberculosis Treatment Segment by Application in 2021
Figure 3. Global Drug-Resistant Tuberculosis Treatment Market Overview: 2021
Figure 4. Key Caveats
Figure 5. Global Drug-Resistant Tuberculosis Treatment Market Size: 2021 VS 2028 (US$, Mn)
Figure 6. Global Drug-Resistant Tuberculosis Treatment Revenue, 2017-2028 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Drug-Resistant Tuberculosis Treatment Revenue in 2021
Figure 8. By Type - Global Drug-Resistant Tuberculosis Treatment Revenue Market Share, 2017-2028
Figure 9. By Application - Global Drug-Resistant Tuberculosis Treatment Revenue Market Share, 2017-2028
Figure 10. By Region - Global Drug-Resistant Tuberculosis Treatment Revenue Market Share, 2017-2028
Figure 11. By Country - North America Drug-Resistant Tuberculosis Treatment Revenue Market Share, 2017-2028
Figure 12. US Drug-Resistant Tuberculosis Treatment Revenue, (US$, Mn), 2017-2028
Figure 13. Canada Drug-Resistant Tuberculosis Treatment Revenue, (US$, Mn), 2017-2028
Figure 14. Mexico Drug-Resistant Tuberculosis Treatment Revenue, (US$, Mn), 2017-2028
Figure 15. By Country - Europe Drug-Resistant Tuberculosis Treatment Revenue Market Share, 2017-2028
Figure 16. Germany Drug-Resistant Tuberculosis Treatment Revenue, (US$, Mn), 2017-2028
Figure 17. France Drug-Resistant Tuberculosis Treatment Revenue, (US$, Mn), 2017-2028
Figure 18. U.K. Drug-Resistant Tuberculosis Treatment Revenue, (US$, Mn), 2017-2028
Figure 19. Italy Drug-Resistant Tuberculosis Treatment Revenue, (US$, Mn), 2017-2028
Figure 20. Russia Drug-Resistant Tuberculosis Treatment Revenue, (US$, Mn), 2017-2028
Figure 21. Nordic Countries Drug-Resistant Tuberculosis Treatment Revenue, (US$, Mn), 2017-2028
Figure 22. Benelux Drug-Resistant Tuberculosis Treatment Revenue, (US$, Mn), 2017-2028
Figure 23. By Region - Asia Drug-Resistant Tuberculosis Treatment Revenue Market Share, 2017-2028
Figure 24. China Drug-Resistant Tuberculosis Treatment Revenue, (US$, Mn), 2017-2028
Figure 25. Japan Drug-Resistant Tuberculosis Treatment Revenue, (US$, Mn), 2017-2028
Figure 26. South Korea Drug-Resistant Tuberculosis Treatment Revenue, (US$, Mn), 2017-2028
Figure 27. Southeast Asia Drug-Resistant Tuberculosis Treatment Revenue, (US$, Mn), 2017-2028
Figure 28. India Drug-Resistant Tuberculosis Treatment Revenue, (US$, Mn), 2017-2028
Figure 29. By Country - South America Drug-Resistant Tuberculosis Treatment Revenue Market Share, 2017-2028
Figure 30. Brazil Drug-Resistant Tuberculosis Treatment Revenue, (US$, Mn), 2017-2028
Figure 31. Argentina Drug-Resistant Tuberculosis Treatment Revenue, (US$, Mn), 2017-2028
Figure 32. By Country - Middle East & Africa Drug-Resistant Tuberculosis Treatment Revenue Market Share, 2017-2028
Figure 33. Turkey Drug-Resistant Tuberculosis Treatment Revenue, (US$, Mn), 2017-2028
Figure 34. Israel Drug-Resistant Tuberculosis Treatment Revenue, (US$, Mn), 2017-2028
Figure 35. Saudi Arabia Drug-Resistant Tuberculosis Treatment Revenue, (US$, Mn), 2017-2028
Figure 36. UAE Drug-Resistant Tuberculosis Treatment Revenue, (US$, Mn), 2017-2028
Figure 37. Sanofi Drug-Resistant Tuberculosis Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 38. Novartis AG Drug-Resistant Tuberculosis Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 39. Endo International plc Drug-Resistant Tuberculosis Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 40. CMP Pharma Drug-Resistant Tuberculosis Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 41. STI Pharma LLC Drug-Resistant Tuberculosis Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 42. Akorn Incorporated Drug-Resistant Tuberculosis Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 43. Lupin Drug-Resistant Tuberculosis Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 44. Johnson & Johnson Services Inc. Drug-Resistant Tuberculosis Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 45. Macleods Pharmaceuticals Ltd Drug-Resistant Tuberculosis Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 46. Pfizer Inc Drug-Resistant Tuberculosis Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 47. Hikma Pharmaceuticals PLC Drug-Resistant Tuberculosis Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 48. Lannett Drug-Resistant Tuberculosis Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 49. Mylan N.V. Drug-Resistant Tuberculosis Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 50. Teva Pharmaceutical Industries Ltd Drug-Resistant Tuberculosis Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 51. Fresenius Kabi AG Drug-Resistant Tuberculosis Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)